サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1555598

CMO/CDMOバイオテクノロジー市場：世界の産業分析、規模、シェア、成長、動向、2024-2033年予測

CMO/CDMO Biotechnology Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

出版日
ページ情報
英文 319 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
CMO/CDMOバイオテクノロジー市場：世界の産業分析、規模、シェア、成長、動向、2024-2033年予測
出版日: 2024年09月06日
発行: Persistence Market Research
ページ情報: 英文 319 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Research社はこのほど、世界のCMO/CDMO（医薬品製造受託機関/研究開発受託機関）バイオテクノロジー市場の詳細な分析を発表しました。当レポートでは、成長促進要因、動向、市場促進要因・課題を含む主要な市場ダイナミクスを包括的に評価し、市場展望の徹底的な理解を提供します。

主な洞察

  • CMO/CDMOバイオテクノロジー市場規模（2024E）：231億米ドル
  • 予測市場価値（2033F）：336億米ドル
  • 世界市場成長率（CAGR 2024年から2033年まで）：5.5%

CMO/CDMOバイオテクノロジー市場- 調査範囲：

CMO/CDMOバイオテクノロジー市場は、バイオ医薬品業界における重要なセグメントであり、バイオテクノロジー製品の製造および市場開拓サービスのアウトソーシングに焦点を当てています。この市場には、専門組織がバイオ医薬品企業に提供する医薬品開発、製造、商業化などの幅広いサービスが含まれます。この分野の特徴は、医薬品開発期間の短縮、運営コストの削減、製造能力の強化に果たす役割にあります。市場の拡大は、バイオテクノロジー治療に対する需要の高まり、医薬品開発の複雑化、柔軟でスケーラブルな製造ソリューションの必要性などが背景にあります。

市場成長の促進要因：

CMO/CDMOバイオテクノロジー市場は、生物製剤や個別化医療に対する需要の高まりなど、いくつかの重要な要因によって活性化しています。バイオ医薬品企業は、CMO/CDMOプロバイダーの専門知識、高度な技術、コスト効率を活用するため、製造のアウトソーシングをますます進めています。生物製剤や複雑な医薬品へのシフトは、迅速な市場参入と柔軟性の必要性と相まって、CMO/CDMOセクターの成長を後押ししています。さらに、慢性疾患の増加や新薬治療への注目の高まりも、バイオ医薬品製造サービスのアウトソーシング需要の高まりに寄与しています。

市場抑制要因：

成長の可能性はあるもの、CMO/CDMOバイオテクノロジー市場は、規制の複雑さ、知的財産権に関する懸念、競争の激化といった課題に直面しています。バイオテクノロジー製品の規制状況を乗り切るには、厳格な基準を遵守する必要があり、CMO/CDMOプロバイダーにとっては困難が伴う。また、製剤や製法に関する知的財産の問題もリスクとなりうる。さらに、市場競争は激しく、多数の企業が契約を争っているため、価格設定や利益率に影響を与える可能性があります。

市場機会：

CMO/CDMOバイオテクノロジー市場は、技術の進歩、バイオ医薬品への投資の増加、治療領域の拡大により、大きな成長機会を提供しています。シングルユースシステムや連続製造などのバイオ製造技術の革新は、市場プレーヤーに効率向上とコスト削減の機会を提供します。生物製剤や遺伝子治療の台頭は、CMO/CDMOプロバイダーがニッチセグメントに対応し、専門サービスを開発する新たな道を開く。また、CMO/CDMO企業とバイオ製薬企業との戦略的提携は、市場の成長を促し、イノベーションを促進する可能性があります。

本レポートで扱う主な質問

  • 世界のCMO/CDMOバイオテクノロジー市場の成長を促す主な要因は何か？
  • 大きな需要があるCMO/CDMOサービスと治療分野は？
  • 技術の進歩はCMO/CDMO市場の競合情勢をどのように変えているのか？
  • CMO/CDMOバイオテクノロジー市場の主要プレーヤーは誰で、競争力を維持するためにどのような戦略をとっているのか？
  • 世界のCMO/CDMOバイオテクノロジー市場の新たな動向と将来性は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲/ 分類
  • 市場の定義/ 範囲/ 制限
  • 包含と除外

第3章 主要な市場動向

  • 市場に影響を与える主な動向
  • イノベーション/開発動向

第4章 重要成功要因

  • サービス採用分析
  • 主な規制
  • 主要プレーヤーによる主要なプロモーション戦略
  • PESTEL分析
  • サービス価格分析

第5章 市場背景

  • マクロ経済要因
  • 予測要因- 関連性と影響
  • 市場力学

第6章 COVID-19危機分析

  • COVID-19と影響分析
    • サービス別
    • 製品別
    • 表現システム別
    • 企業規模別
    • 事業規模別
    • 国別
  • 2024年の市場シナリオ

第7章 世界のCMO/CDMOバイオテクノロジー市場の需要（金額または規模、10億米ドル）分析

  • 市場金額（10億米ドル）分析、2019～2023年
  • 市場金額（10億米ドル）予測、2024～2033年
    • 前年比成長動向分析
    • 絶対的収益機会

第8章 世界のCMO/CDMOバイオテクノロジー市場分析：サービス別

  • イントロダクション/主な調査結果
  • 市場規模（10億米ドル）分析、2019～2023年
  • 市場規模（10億米ドル）分析と予測、2024～2033年
    • スタンドアロンサービス
      • 細胞株の開発
      • 開発とバイオ製造
      • 分析サービス
      • 充填仕上げ
      • パッケージ
      • 臨床供給サービス
    • 統合型
  • サービス別市場の魅力分析

第9章 世界のCMO/CDMOバイオテクノロジー市場分析：製品別

  • イントロダクション/主な調査結果
  • 市場規模（10億米ドル）分析、2019～2023年
  • 市場規模（10億米ドル）分析と予測、2024～2033年
    • モノクローナル抗体
    • 抗体断片
    • 組み換え治療用タンパク質
    • ウイルスベクター
    • 細胞および遺伝子治療
    • ワクチン
  • 製品別市場の魅力分析

第10章 世界のCMO/CDMOバイオテクノロジー市場分析：発現システム別

  • イントロダクション/主な調査結果
  • 市場規模（10億米ドル）分析、2019～2023年
  • 市場規模（10億米ドル）分析と予測、2024～2033年
    • 哺乳類
    • 微生物
      • 細菌
      • 酵母
  • 発現システム別市場の魅力分析

第11章 世界のCMO/CDMOバイオテクノロジー市場分析：企業規模別

  • イントロダクション/主な調査結果
  • 市場規模（10億米ドル）分析、2019～2023年
  • 市場規模（10億米ドル）分析と予測、2024～2033年
    • 小規模
    • 中規模
    • 大規模
    • 超大規模
  • 企業規模別市場の魅力分析

第12章 世界のCMO/CDMOバイオテクノロジー市場分析：運用規模別

  • イントロダクション/主な調査結果
  • 市場規模（10億米ドル）分析、2019～2023年
  • 市場規模（10億米ドル）分析と予測、2024～2033年
    • 前臨床
    • 臨床
    • 商業
  • 運用規模別市場の魅力分析

第13章 世界のCMO/CDMOバイオテクノロジー市場分析：地域別

  • イントロダクション
  • 市場規模（10億米ドル）分析、2019～2023年
  • 市場規模（10億米ドル）分析と予測、2024～2033年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東およびアフリカ
  • 地域別市場の魅力分析

第14章 北米CMO/CDMOバイオテクノロジー市場分析

第15章 ラテンアメリカのCMO/CDMOバイオテクノロジー市場分析

第16章 欧州のCMO/CDMOバイオテクノロジー市場分析

第17章 東アジアのCMO/CDMOバイオテクノロジー市場分析

第18章 南アジアのCMO/CDMOバイオテクノロジー市場分析

第19章 オセアニアのCMO/CDMOバイオテクノロジー市場

第20章 中東およびアフリカCMO/CDMOバイオテクノロジー市場分析

第21章 市場構造分析

  • 企業階層別市場分析
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第22章 競合分析

  • 競合ダッシュボード
  • 競合の詳細
    • Patheon NV
    • Catalent
    • Samsung Biologics Co., Ltd
    • Lonza.
    • Boehringer Ingelheim
    • Samsung BioLogics
    • AGC Biologics, Inc.
    • WuXi Biologics
    • AbbVie Inc
    • Avid Bioservices, Inc.
    • Fujifilm Diosynth Biotechnologies
    • Xpress Biologic
    • Rentschler Biopharma SE
    • KBI Biopharma（JSR Corporation）
    • Cytovance Biologics

第23章 使用される前提条件と頭字語

第24章 調査手法

目次
Product Code: PMRREP32516

Persistence Market Research has recently published an in-depth analysis of the global CMO/CDMO (Contract Manufacturing Organization/Contract Development and Manufacturing Organization) biotechnology market. The report provides a comprehensive evaluation of key market dynamics, including growth drivers, trends, opportunities, and challenges, delivering a thorough understanding of the market landscape.

Key Insights:

  • CMO/CDMO Biotechnology Market Size (2024E): USD 23.1 Bn
  • Projected Market Value (2033F): USD 33.6 Bn
  • Global Market Growth Rate (CAGR 2024 to 2033): 5.5%

CMO/CDMO Biotechnology Market - Report Scope:

The CMO/CDMO biotechnology market represents a crucial segment in the biopharmaceutical industry, focusing on the outsourcing of manufacturing and development services for biotech products. This market includes a wide range of services, such as drug development, manufacturing, and commercialization, provided by specialized organizations to biopharma companies. The sector is characterized by its role in accelerating drug development timelines, reducing operational costs, and enhancing manufacturing capabilities. The market's expansion is driven by the growing demand for biotech therapies, increasing complexity in drug development, and the need for flexible and scalable manufacturing solutions.

Market Growth Drivers:

The CMO/CDMO biotechnology market is fueled by several key factors, including the rising demand for biologics and personalized medicine. Biopharma companies are increasingly outsourcing manufacturing to CMO/CDMO providers to leverage their specialized expertise, advanced technologies, and cost efficiencies. The shift towards biologics and complex drugs, coupled with the need for rapid market entry and flexibility, drives the growth of the CMO/CDMO sector. Additionally, the increasing prevalence of chronic diseases and the growing focus on novel drug therapies contribute to the rising demand for outsourced biotech manufacturing services.

Market Restraints:

Despite its growth potential, the CMO/CDMO biotechnology market faces challenges such as regulatory complexities, intellectual property concerns, and high competition. Navigating the regulatory landscape for biotech products requires adherence to stringent standards, which can be challenging for CMO/CDMO providers. Intellectual property issues related to drug formulations and processes may also pose risks. Furthermore, the market is highly competitive, with numerous players vying for contracts, which can impact pricing and profit margins.

Market Opportunities:

The CMO/CDMO biotechnology market offers substantial growth opportunities driven by technological advancements, increasing investments in biopharma, and expanding therapeutic areas. Innovations in biomanufacturing technologies, such as single-use systems and continuous manufacturing, present opportunities for market players to enhance efficiency and reduce costs. The rise of biologics and gene therapies opens new avenues for CMO/CDMO providers to cater to niche segments and develop specialized services. Strategic collaborations between CMO/CDMO firms and biopharma companies can also drive market growth and foster innovation.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the CMO/CDMO biotechnology market globally?
  • Which CMO/CDMO services and therapeutic areas are experiencing significant demand?
  • How are technological advancements reshaping the competitive landscape of the CMO/CDMO market?
  • Who are the key players in the CMO/CDMO biotechnology market, and what strategies are they employing to maintain a competitive edge?
  • What are the emerging trends and future prospects in the global CMO/CDMO biotechnology market?

Competitive Intelligence and Business Strategy:

Leading players in the global CMO/CDMO biotechnology market, such as Lonza Group, Catalent, and Samsung Biologics, emphasize innovation, service differentiation, and strategic partnerships to enhance their market position. These companies invest in advanced manufacturing technologies, expand their service portfolios, and forge alliances with biopharma firms to strengthen their competitive edge. Focus on operational excellence, regulatory compliance, and customer-centric solutions is critical for maintaining market relevance and driving growth in the highly competitive CMO/CDMO sector.

Key Companies Profiled:

  • Patheon N.V.
  • Catalent
  • Samsung Biologics Co., Ltd
  • Lonza.
  • Boehringer Ingelheim
  • Samsung BioLogics
  • AGC Biologics, Inc.
  • WuXi Biologics
  • AbbVie Inc
  • Avid Bioservices, Inc.
  • Fujifilm Diosynth Biotechnologies
  • Xpress Biologic
  • Rentschler Biopharma SE
  • KBI Biopharma (JSR Corporation)
  • Cytovance Biologics

Key Segments Covered in CMO/CDMO Biotechnology Industry Research

By Service:

  • Stand-Alone Services
  • Integrated

By Product:

  • Monoclonal Antibodies
  • Antibody Fragments
  • Recombinant Therapeutic Proteins
  • Viral Vector
  • Cell and Gene Therapy
  • Vaccine

By Expression System:

  • Mammalian
  • Microbial
  • Bacteria
  • Yeast

By Company Size:

  • Small
  • Mid-Sized
  • Large
  • Very Large

By Scale of Operations:

  • Pre-clinical
  • Clinical
  • Commercial

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa (MEA)

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Innovation / Development Trends

4. Key Success Factors

  • 4.1. Service Adoption Analysis
  • 4.2. Key Regulations
  • 4.3. Key promotional Strategies, By Key Players
  • 4.4. PESTEL Analysis
  • 4.5. Service Pricing Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Outlook
    • 5.1.3. Global CMO/CDMO Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Increase in R&D Spending
    • 5.2.2. Growing Lifestyle Disease Prevalence
    • 5.2.3. Cost of Services
    • 5.2.4. Service Adoption Rate
    • 5.2.5. Advancements in Technology
    • 5.2.6. Changes in Regulatory Policies
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Services
    • 6.1.2. By Product
    • 6.1.3. By Expression Systems
    • 6.1.4. By Company Size
    • 6.1.5. By Scale of Operations
    • 6.1.6. By Country
  • 6.2. 2024 Market Scenario

7. Global CMO/CDMO Biotechnology Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

  • 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Services

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Bn) Analysis By Services, 2019-2023
  • 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Services, 2024-2033
    • 8.3.1. Stand-Alone Services
      • 8.3.1.1. Cell Line Development
      • 8.3.1.2. Development and Bio Manufacturing
      • 8.3.1.3. Analytical Services
      • 8.3.1.4. Fill finish
      • 8.3.1.5. Packaging
      • 8.3.1.6. Clinical Supply Services
    • 8.3.2. Integrated
  • 8.4. Market Attractiveness Analysis By Services

9. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Product

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Product, 2019-2023
  • 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Product, 2024-2033
    • 9.3.1. Monoclonal Antibodies
    • 9.3.2. Antibody Fragments
    • 9.3.3. Recombinant Therapeutic Proteins
    • 9.3.4. Viral Vector
    • 9.3.5. Cell and Gene Therapy
    • 9.3.6. Vaccine
  • 9.4. Market Attractiveness Analysis By Product

10. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Expression Systems

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Expression Systems, 2019-2023
  • 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Expression Systems, 2024-2033
    • 10.3.1. Mammalian
    • 10.3.2. Microbial
      • 10.3.2.1. Bacteria
      • 10.3.2.2. Yeast
  • 10.4. Market Attractiveness Analysis By Expression Systems

11. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Company Size

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Company Size, 2019-2023
  • 11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Company Size, 2024-2033
    • 11.3.1. Small
    • 11.3.2. Mid-sized
    • 11.3.3. Large
    • 11.3.4. Very large
  • 11.4. Market Attractiveness Analysis By Company Size

12. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Scale of Operation

  • 12.1. Introduction / Key Findings
  • 12.2. Historical Market Size (US$ Bn) Analysis, By Scale of Operation, 2019-2023
  • 12.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Scale of Operation, 2024-2033
    • 12.3.1. Preclinical
    • 12.3.2. Clinical
    • 12.3.3. Commercial
  • 12.4. Market Attractiveness Analysis By Scale of Operation

13. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Region

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
  • 13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2024-2033
    • 13.3.1. North America
    • 13.3.2. Latin America
    • 13.3.3. Europe
    • 13.3.4. East Asia
    • 13.3.5. South Asia
    • 13.3.6. Oceania
    • 13.3.7. Middle East and Africa (MEA)
  • 13.4. Market Attractiveness Analysis By Region

14. North America CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 14.3.1. By Country
      • 14.3.1.1. U.S.
      • 14.3.1.2. Canada
    • 14.3.2. By Services
    • 14.3.3. By Product
    • 14.3.4. By Expression Systems
    • 14.3.5. By Company Size
    • 14.3.6. By Scale of Operation
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Services
    • 14.4.3. By Product
    • 14.4.4. By Expression Systems
    • 14.4.5. By Company Size
    • 14.4.6. By Scale of Operation
  • 14.5. Market Trends
  • 14.6. Drivers and Restraints - Impact Analysis
  • 14.7. Key Players - Intensity Mapping
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. U.S. CMO/CDMO Biotechnology Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Services
        • 14.8.1.2.2. By Product
        • 14.8.1.2.3. By Expression Systems
        • 14.8.1.2.4. By Company Size
        • 14.8.1.2.5. By Scale of Operation
    • 14.8.2. Canada CMO/CDMO Biotechnology Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Services
        • 14.8.2.2.2. By Product
        • 14.8.2.2.3. By Expression Systems
        • 14.8.2.2.4. By Company Size
        • 14.8.2.2.5. By Scale of Operation

15. Latin America CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 15.3.1. By Country
      • 15.3.1.1. Mexico
      • 15.3.1.2. Brazil
      • 15.3.1.3. Argentina
      • 15.3.1.4. Rest of Latin America
    • 15.3.2. By Services
    • 15.3.3. By Product
    • 15.3.4. By Expression Systems
    • 15.3.5. By Company Size
    • 15.3.6. By Scale of Operation
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Services
    • 15.4.3. By Product
    • 15.4.4. By Expression Systems
    • 15.4.5. By Company Size
    • 15.4.6. By Scale of Operation
  • 15.5. Market Trends
  • 15.6. Drivers and Restraints - Impact Analysis
  • 15.7. Key Players - Intensity Mapping
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. Mexico CMO/CDMO Biotechnology Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Services
        • 15.8.1.2.2. By Product
        • 15.8.1.2.3. By Expression Systems
        • 15.8.1.2.4. By Company Size
        • 15.8.1.2.5. By Scale of Operation
    • 15.8.2. Brazil CMO/CDMO Biotechnology Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Services
        • 15.8.2.2.2. By Product
        • 15.8.2.2.3. By Expression Systems
        • 15.8.2.2.4. By Company Size
        • 15.8.2.2.5. By Scale of Operation
    • 15.8.3. Argentina CMO/CDMO Biotechnology Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Services
        • 15.8.3.2.2. By Product
        • 15.8.3.2.3. By Expression Systems
        • 15.8.3.2.4. By Company Size
        • 15.8.3.2.5. By Scale of Operation

16. Europe CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 16.3.1. By Country
      • 16.3.1.1. Germany
      • 16.3.1.2. Italy
      • 16.3.1.3. France
      • 16.3.1.4. U.K.
      • 16.3.1.5. Spain
      • 16.3.1.6. BENELUX
      • 16.3.1.7. Russia
      • 16.3.1.8. Rest of Europe
    • 16.3.2. By Services
    • 16.3.3. By Product
    • 16.3.4. By Expression Systems
    • 16.3.5. By Company Size
    • 16.3.6. By Scale of Operation
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Services
    • 16.4.3. By Product
    • 16.4.4. By Expression Systems
    • 16.4.5. By Company Size
    • 16.4.6. By Scale of Operation
  • 16.5. Market Trends
  • 16.6. Drivers and Restraints - Impact Analysis
  • 16.7. Key Players - Intensity Mapping
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. Germany CMO/CDMO Biotechnology Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Services
        • 16.8.1.2.2. By Product
        • 16.8.1.2.3. By Expression Systems
        • 16.8.1.2.4. By Company Size
        • 16.8.1.2.5. By Scale of Operation
    • 16.8.2. Italy CMO/CDMO Biotechnology Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Services
        • 16.8.2.2.2. By Product
        • 16.8.2.2.3. By Expression Systems
        • 16.8.2.2.4. By Company Size
        • 16.8.2.2.5. By Scale of Operation
    • 16.8.3. France CMO/CDMO Biotechnology Market Analysis
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.3.2.1. By Services
        • 16.8.3.2.2. By Product
        • 16.8.3.2.3. By Expression Systems
        • 16.8.3.2.4. By Company Size
        • 16.8.3.2.5. By Scale of Operation
    • 16.8.4. U.K. CMO/CDMO Biotechnology Market Analysis
      • 16.8.4.1. Introduction
      • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.4.2.1. By Services
        • 16.8.4.2.2. By Product
        • 16.8.4.2.3. By Expression Systems
        • 16.8.4.2.4. By Company Size
        • 16.8.4.2.5. By Scale of Operation
    • 16.8.5. Spain CMO/CDMO Biotechnology Market Analysis
      • 16.8.5.1. Introduction
      • 16.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.5.2.1. By Services
        • 16.8.5.2.2. By Product
        • 16.8.5.2.3. By Expression Systems
        • 16.8.5.2.4. By Company Size
        • 16.8.5.2.5. By Scale of Operation
    • 16.8.6. BENELUX CMO/CDMO Biotechnology Market Analysis
      • 16.8.6.1. Introduction
      • 16.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.6.2.1. By Services
        • 16.8.6.2.2. By Product
        • 16.8.6.2.3. By Expression Systems
        • 16.8.6.2.4. By Company Size
        • 16.8.6.2.5. By Scale of Operation
    • 16.8.7. Russia CMO/CDMO Biotechnology Market Analysis
      • 16.8.7.1. Introduction
      • 16.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.7.2.1. By Services
        • 16.8.7.2.2. By Product
        • 16.8.7.2.3. By Expression Systems
        • 16.8.7.2.4. By Company Size
        • 16.8.7.2.5. By Scale of Operation

17. East Asia CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 17.3.1. By Country
      • 17.3.1.1. China
      • 17.3.1.2. Japan
      • 17.3.1.3. South Korea
    • 17.3.2. By Services
    • 17.3.3. By Product
    • 17.3.4. By Expression Systems
    • 17.3.5. By Company Size
    • 17.3.6. By Scale of Operation
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Services
    • 17.4.3. By Product
    • 17.4.4. By Expression Systems
    • 17.4.5. By Company Size
    • 17.4.6. By Scale of Operation
  • 17.5. Market Trends
  • 17.6. Drivers and Restraints - Impact Analysis
  • 17.7. Key Players - Intensity Mapping
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. China CMO/CDMO Biotechnology Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Services
        • 17.8.1.2.2. By Product
        • 17.8.1.2.3. By Expression Systems
        • 17.8.1.2.4. By Company Size
        • 17.8.1.2.5. By Scale of Operation
    • 17.8.2. Japan CMO/CDMO Biotechnology Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Services
        • 17.8.2.2.2. By Product
        • 17.8.2.2.3. By Expression Systems
        • 17.8.2.2.4. By Company Size
        • 17.8.2.2.5. By Scale of Operation
    • 17.8.3. South Korea CMO/CDMO Biotechnology Market Analysis
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Services
        • 17.8.3.2.2. By Product
        • 17.8.3.2.3. By Expression Systems
        • 17.8.3.2.4. By Company Size
        • 17.8.3.2.5. By Scale of Operation

18. South Asia CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 18.3.1. By Country
      • 18.3.1.1. India
      • 18.3.1.2. Indonesia
      • 18.3.1.3. Malaysia
      • 18.3.1.4. Thailand
      • 18.3.1.5. Rest of South Asia
    • 18.3.2. By Services
    • 18.3.3. By Product
    • 18.3.4. By Expression Systems
    • 18.3.5. By Company Size
    • 18.3.6. By Scale of Operation
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Services
    • 18.4.3. By Product
    • 18.4.4. By Expression Systems
    • 18.4.5. By Company Size
    • 18.4.6. By Scale of Operation
  • 18.5. Market Trends
  • 18.6. Drivers and Restraints - Impact Analysis
  • 18.7. Key Players - Intensity Mapping
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. India CMO/CDMO Biotechnology Market Analysis
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.1.2.1. By Services
        • 18.8.1.2.2. By Product
        • 18.8.1.2.3. By Expression Systems
        • 18.8.1.2.4. By Company Size
        • 18.8.1.2.5. By Scale of Operation
    • 18.8.2. Indonesia CMO/CDMO Biotechnology Market Analysis
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.2.2.1. By Services
        • 18.8.2.2.2. By Product
        • 18.8.2.2.3. By Expression Systems
        • 18.8.2.2.4. By Company Size
        • 18.8.2.2.5. By Scale of Operation
    • 18.8.3. Malaysia CMO/CDMO Biotechnology Market Analysis
      • 18.8.3.1. Introduction
      • 18.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.3.2.1. By Services
        • 18.8.3.2.2. By Product
        • 18.8.3.2.3. By Expression Systems
        • 18.8.3.2.4. By Company Size
        • 18.8.3.2.5. By Scale of Operation
    • 18.8.4. Thailand CMO/CDMO Biotechnology Market Analysis
      • 18.8.4.1. Introduction
      • 18.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.4.2.1. By Services
        • 18.8.4.2.2. By Product
        • 18.8.4.2.3. By Expression Systems
        • 18.8.4.2.4. By Company Size
        • 18.8.4.2.5. By Scale of Operation

19. Oceania CMO/CDMO Biotechnology Market 2019-2023 and Forecast 2024-2033

  • 19.1. Introduction
  • 19.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 19.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 19.3.1. By Country
      • 19.3.1.1. Australia
      • 19.3.1.2. New Zealand
    • 19.3.2. By Services
    • 19.3.3. By Product
    • 19.3.4. By Expression Systems
    • 19.3.5. By Company Size
    • 19.3.6. By Scale of Operation
  • 19.4. Market Attractiveness Analysis
    • 19.4.1. By Country
    • 19.4.2. By Services
    • 19.4.3. By Product
    • 19.4.4. By Expression Systems
    • 19.4.5. By Company Size
    • 19.4.6. By Scale of Operation
  • 19.5. Market Trends
  • 19.6. Drivers and Restraints - Impact Analysis
  • 19.7. Key Players - Intensity Mapping
  • 19.8. Country Level Analysis & Forecast
    • 19.8.1. Australia CMO/CDMO Biotechnology Market Analysis
      • 19.8.1.1. Introduction
      • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.1.2.1. By Services
        • 19.8.1.2.2. By Product
        • 19.8.1.2.3. By Expression Systems
        • 19.8.1.2.4. By Company Size
        • 19.8.1.2.5. By Scale of Operation
    • 19.8.2. New Zealand CMO/CDMO Biotechnology Market Analysis
      • 19.8.2.1. Introduction
      • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.2.2.1. By Services
        • 19.8.2.2.2. By Product
        • 19.8.2.2.3. By Expression Systems
        • 19.8.2.2.4. By Company Size
        • 19.8.2.2.5. By Scale of Operation

20. Middle East and Africa (MEA) CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033

  • 20.1. Introduction
  • 20.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 20.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 20.3.1. By Country
      • 20.3.1.1. GCC Countries
      • 20.3.1.2. Turkey
      • 20.3.1.3. North Africa
      • 20.3.1.4. South Africa
      • 20.3.1.5. Rest of Middle East and Africa
    • 20.3.2. By Services
    • 20.3.3. By Product
    • 20.3.4. By Expression Systems
    • 20.3.5. By Company Size
    • 20.3.6. By Scale of Operation
  • 20.4. Market Attractiveness Analysis
    • 20.4.1. By Country
    • 20.4.2. By Services
    • 20.4.3. By Product
    • 20.4.4. By Expression Systems
    • 20.4.5. By Company Size
    • 20.4.6. By Scale of Operation
  • 20.5. Market Trends
  • 20.6. Drivers and Restraints - Impact Analysis
  • 20.7. Key Players - Intensity Mapping
  • 20.8. Country Level Analysis & Forecast
    • 20.8.1. GCC Countries CMO/CDMO Biotechnology Market Analysis
      • 20.8.1.1. Introduction
      • 20.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 20.8.1.2.1. By Services
        • 20.8.1.2.2. By Product
        • 20.8.1.2.3. By Expression Systems
        • 20.8.1.2.4. By Company Size
        • 20.8.1.2.5. By Scale of Operation
    • 20.8.2. Turkey CMO/CDMO Biotechnology Market Analysis
      • 20.8.2.1. Introduction
      • 20.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 20.8.2.2.1. By Services
        • 20.8.2.2.2. By Product
        • 20.8.2.2.3. By Expression Systems
        • 20.8.2.2.4. By Company Size
        • 20.8.2.2.5. By Scale of Operation
    • 20.8.3. South Africa CMO/CDMO Biotechnology Market Analysis
      • 20.8.3.1. Introduction
      • 20.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 20.8.3.2.1. By Services
        • 20.8.3.2.2. By Product
        • 20.8.3.2.3. By Expression Systems
        • 20.8.3.2.4. By Company Size
        • 20.8.3.2.5. By Scale of Operation
    • 20.8.4. North Africa CMO/CDMO Biotechnology Market Analysis
      • 20.8.4.1. Introduction
      • 20.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 20.8.4.2.1. By Services
        • 20.8.4.2.2. By Product
        • 20.8.4.2.3. By Expression Systems
        • 20.8.4.2.4. By Company Size
        • 20.8.4.2.5. By Scale of Operation

21. Market Structure Analysis

  • 21.1. Market Analysis by Tier of Companies
  • 21.2. Market Share Analysis of Top Players
  • 21.3. Market Presence Analysis

22. Competition Analysis

  • 22.1. Competition Dashboard
  • 22.2. Competition Deep Dive
    • 22.2.1. Patheon N.V.
      • 22.2.1.1. Overview
      • 22.2.1.2. Service/Product Portfolio
      • 22.2.1.3. Sales Footprint
      • 22.2.1.4. Key Financials
      • 22.2.1.5. SWOT Analysis
      • 22.2.1.6. Strategy Overview
        • 22.2.1.6.1. Marketing Strategy
        • 22.2.1.6.2. Service Strategy
        • 22.2.1.6.3. Channel Strategy
    • 22.2.2. Catalent
      • 22.2.2.1. Overview
      • 22.2.2.2. Service/Product Portfolio
      • 22.2.2.3. Sales Footprint
      • 22.2.2.4. Key Financials
      • 22.2.2.5. SWOT Analysis
      • 22.2.2.6. Strategy Overview
        • 22.2.2.6.1. Marketing Strategy
        • 22.2.2.6.2. Service Strategy
        • 22.2.2.6.3. Channel Strategy
    • 22.2.3. Samsung Biologics Co., Ltd
      • 22.2.3.1. Overview
      • 22.2.3.2. Service/Product Portfolio
      • 22.2.3.3. Sales Footprint
      • 22.2.3.4. Key Financials
      • 22.2.3.5. SWOT Analysis
      • 22.2.3.6. Strategy Overview
        • 22.2.3.6.1. Marketing Strategy
        • 22.2.3.6.2. Service Strategy
        • 22.2.3.6.3. Channel Strategy
    • 22.2.4. Lonza.
      • 22.2.4.1. Overview
      • 22.2.4.2. Service/Product Portfolio
      • 22.2.4.3. Sales Footprint
      • 22.2.4.4. Key Financials
      • 22.2.4.5. SWOT Analysis
      • 22.2.4.6. Strategy Overview
        • 22.2.4.6.1. Marketing Strategy
        • 22.2.4.6.2. Service Strategy
        • 22.2.4.6.3. Channel Strategy
    • 22.2.5. Boehringer Ingelheim
      • 22.2.5.1. Overview
      • 22.2.5.2. Service/Product Portfolio
      • 22.2.5.3. Sales Footprint
      • 22.2.5.4. Key Financials
      • 22.2.5.5. SWOT Analysis
      • 22.2.5.6. Strategy Overview
        • 22.2.5.6.1. Marketing Strategy
        • 22.2.5.6.2. Service Strategy
        • 22.2.5.6.3. Channel Strategy
    • 22.2.6. Samsung BioLogics
      • 22.2.6.1. Overview
      • 22.2.6.2. Service/Product Portfolio
      • 22.2.6.3. Sales Footprint
      • 22.2.6.4. Key Financials
      • 22.2.6.5. SWOT Analysis
      • 22.2.6.6. Strategy Overview
        • 22.2.6.6.1. Marketing Strategy
        • 22.2.6.6.2. Service Strategy
        • 22.2.6.6.3. Channel Strategy
    • 22.2.7. AGC Biologics, Inc.
      • 22.2.7.1. Overview
      • 22.2.7.2. Service/Product Portfolio
      • 22.2.7.3. Sales Footprint
      • 22.2.7.4. Key Financials
      • 22.2.7.5. SWOT Analysis
      • 22.2.7.6. Strategy Overview
        • 22.2.7.6.1. Marketing Strategy
        • 22.2.7.6.2. Service Strategy
        • 22.2.7.6.3. Channel Strategy
    • 22.2.8. WuXi Biologics
      • 22.2.8.1. Overview
      • 22.2.8.2. Service/Product Portfolio
      • 22.2.8.3. Sales Footprint
      • 22.2.8.4. Key Financials
      • 22.2.8.5. SWOT Analysis
      • 22.2.8.6. Strategy Overview
        • 22.2.8.6.1. Marketing Strategy
        • 22.2.8.6.2. Service Strategy
        • 22.2.8.6.3. Channel Strategy
    • 22.2.9. AbbVie Inc
      • 22.2.9.1. Overview
      • 22.2.9.2. Service/Product Portfolio
      • 22.2.9.3. Sales Footprint
      • 22.2.9.4. Key Financials
      • 22.2.9.5. SWOT Analysis
      • 22.2.9.6. Strategy Overview
        • 22.2.9.6.1. Marketing Strategy
        • 22.2.9.6.2. Service Strategy
        • 22.2.9.6.3. Channel Strategy
    • 22.2.10. Avid Bioservices, Inc.
      • 22.2.10.1. Overview
      • 22.2.10.2. Service/Product Portfolio
      • 22.2.10.3. Sales Footprint
      • 22.2.10.4. Key Financials
      • 22.2.10.5. SWOT Analysis
      • 22.2.10.6. Strategy Overview
        • 22.2.10.6.1. Marketing Strategy
        • 22.2.10.6.2. Service Strategy
        • 22.2.10.6.3. Channel Strategy
    • 22.2.11. Fujifilm Diosynth Biotechnologies
      • 22.2.11.1. Overview
      • 22.2.11.2. Service/Product Portfolio
      • 22.2.11.3. Sales Footprint
      • 22.2.11.4. Key Financials
      • 22.2.11.5. SWOT Analysis
      • 22.2.11.6. Strategy Overview
        • 22.2.11.6.1. Marketing Strategy
        • 22.2.11.6.2. Service Strategy
        • 22.2.11.6.3. Channel Strategy
    • 22.2.12. Xpress Biologic
      • 22.2.12.1. Overview
      • 22.2.12.2. Service/Product Portfolio
      • 22.2.12.3. Sales Footprint
      • 22.2.12.4. Key Financials
      • 22.2.12.5. SWOT Analysis
      • 22.2.12.6. Strategy Overview
        • 22.2.12.6.1. Marketing Strategy
        • 22.2.12.6.2. Service Strategy
        • 22.2.12.6.3. Channel Strategy
    • 22.2.13. Rentschler Biopharma SE
      • 22.2.13.1. Overview
      • 22.2.13.2. Service/Product Portfolio
      • 22.2.13.3. Sales Footprint
      • 22.2.13.4. Key Financials
      • 22.2.13.5. SWOT Analysis
      • 22.2.13.6. Strategy Overview
        • 22.2.13.6.1. Marketing Strategy
        • 22.2.13.6.2. Service Strategy
        • 22.2.13.6.3. Channel Strategy
    • 22.2.14. KBI Biopharma (JSR Corporation)
      • 22.2.14.1. Overview
      • 22.2.14.2. Service/Product Portfolio
      • 22.2.14.3. Sales Footprint
      • 22.2.14.4. Key Financials
      • 22.2.14.5. SWOT Analysis
      • 22.2.14.6. Strategy Overview
        • 22.2.14.6.1. Marketing Strategy
        • 22.2.14.6.2. Service Strategy
        • 22.2.14.6.3. Channel Strategy
    • 22.2.15. Cytovance Biologics
      • 22.2.15.1. Overview
      • 22.2.15.2. Service/Product Portfolio
      • 22.2.15.3. Sales Footprint
      • 22.2.15.4. Key Financials
      • 22.2.15.5. SWOT Analysis
      • 22.2.15.6. Strategy Overview
        • 22.2.15.6.1. Marketing Strategy
        • 22.2.15.6.2. Service Strategy
        • 22.2.15.6.3. Channel Strategy

23. Assumptions and Acronyms Used

24. Research Methodology